Shidham Vinod B, Qi Dan, Rao R Nagarjun, Acker Scott M, Chang Chung-Che, Kampalath Bal, Dawson Glen, Machhi Jinobya K, Komorowski Richard A
Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
BMC Cancer. 2003 May 7;3:15. doi: 10.1186/1471-2407-3-15.
MART-1, Melan-A, and Tyrosinase have shown encouraging results for evaluation of melanoma micrometastases in sentinel lymph nodes, as compared to conventionally used S-100 protein and HMB-45. To achieve higher sensitivity, some studies recommend evaluation of three sections, each at intervals of 200 micron. This would mean, routine staining of three adjacent sections in each of the three clusters at intervals of 200 micron, requiring nine slides resulting in added expense. If a cocktail of these antibodies could be used, only one section would be required instead of three generating significant cost savings.
We prepared a combination of monoclonal antibodies to these three immunomarkers in optimized dilutions (MART-1, clone M2-7C10, dilution 1:500; Melan-A, clone A103, dilution 1:100; and Tyrosinase, clone T311, dilution 1:50) and designated it as 'MCW melanoma cocktail'. Formalin-fixed paraffin-embedded tissue sections of sentinel lymph nodes from patients with cutaneous melanoma, without macro-metastases were evaluated with this cocktail.
Melanoma micrometastases were easily detectable with the cocktail in 41 out of 188 slices (8/24 cases). The diagnostic accuracy amongst five pathologists did not show statistically significant difference. Out of 188 slices, 78 had adjacent sections immunostained individually with MART-1 and Melan-A during our previous study. Of these 78 slices, 21 were positive for melanoma micrometastases with MART-1 and Melan-A individually. However, the adjacent section of these slices immunostained with the cocktail detected metastases in four additional slices. Thus, MART-1 and Melan-A could not detect melanoma micrometastases individually in 16% (4/25) of slices positive with the cocktail. Benign capsular nevi were immunoreactive for the cocktail in 4.8% (9/188) slices. All 81 slices of negative test controls (sentinel lymph nodes of mammary carcinoma) were interpreted correctly as negative for melanoma micrometastases.
The melanoma cocktail facilitated easy interpretation of melanoma micrometastases in sentinel lymph nodes with high interobserver agreement. There was improvement in detection rate with the cocktail as compared to MART-1 and Melan-A individually. Furthermore, this approach facilitates cost savings.
与传统使用的S-100蛋白和HMB-45相比,MART-1、Melan-A和酪氨酸酶在评估前哨淋巴结中的黑色素瘤微转移方面已显示出令人鼓舞的结果。为了获得更高的敏感性,一些研究建议对三个切片进行评估,每个切片间隔200微米。这意味着,对三个簇中的每一个簇的三个相邻切片以200微米的间隔进行常规染色,需要九张玻片,从而增加了费用。如果可以使用这些抗体的混合物,那么只需要一个切片而不是三个,可显著节省成本。
我们以优化的稀释度制备了针对这三种免疫标志物的单克隆抗体组合(MART-1,克隆M2-7C10,稀释度1:500;Melan-A,克隆A103,稀释度1:100;酪氨酸酶,克隆T311,稀释度1:50),并将其命名为“MCW黑色素瘤混合物”。使用该混合物对皮肤黑色素瘤患者的前哨淋巴结经福尔马林固定石蜡包埋的组织切片进行评估,这些患者无宏观转移。
在188个切片中的41个(24例中的8例)中,使用该混合物很容易检测到黑色素瘤微转移。五位病理学家之间的诊断准确性没有显示出统计学上的显著差异。在188个切片中,在我们之前的研究中有78个切片的相邻切片分别用MART-1和Melan-A进行免疫染色。在这78个切片中,有21个切片分别用MART-1和Melan-A检测到黑色素瘤微转移呈阳性。然而,用该混合物免疫染色的这些切片的相邻切片在另外四个切片中检测到转移。因此,在混合物检测呈阳性的切片中,MART-1和Melan-A分别有16%(4/25)未能检测到黑色素瘤微转移。良性包膜痣在4.8%(9/188)的切片中对该混合物有免疫反应。所有81个阴性测试对照切片(乳腺癌的前哨淋巴结)均被正确解释为黑色素瘤微转移阴性。
黑色素瘤混合物有助于在前哨淋巴结中轻松解读黑色素瘤微转移,观察者间一致性高。与单独使用MART-1和Melan-A相比,使用该混合物的检测率有所提高。此外,这种方法有助于节省成本。